But, as Celyad bows out, how do you compete in a field as crowded as this?
Meanwhile, there was bad blood between cell therapy players and their investors.
Roche and Bristol Myers Squibb look to have the industry’s next most advanced assets against GPRC5D.
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.